For sales

Highlights from the Week of 13th April – 20th April in the world of pharma and healthcare!

Highlights from the week of 13th April - 20th April Travere Therapeutics ( FDA, Approval ) Travere Therapeutics' FILSPARI gets FDA approval to reduce proteinuria in focal segmental glomerulosclerosis without nephrotic syndrome Alembic ( FDA, Approval ) Alembic gains FDA approval for methotrexate injection USP, 50 mg/2 mL (25 mg/mL) multi-dose vials & 1 g/40 mL (25 mg/mL) single-dose vials for the treatment of neoplastic diseases ARS Pharma ( Health Canada, Approval ) Health Canada approves ARS Pharma's NEFFY 2 mg for the emergency treatment of allergic reactions in those who weigh 30 kg or more, offering a new delivery method for epinephrine Merck ( FDA, Priority Review ) Merck receives Priority Review for ifinatamab deruxtecan, for the treatment of adult patients with extensive-stage small cell lung cancer All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.